The process of in vivo clot dissolution, termed thrombolysis,l is complex, involving the interaction of clot components with the surrounding plasma. Participating in this interaction are plasminogen, plasminogen activator, plasmin, the plasmin inhibitory activity of plasma, and fibrin (1). Although much is known of the nature and quantities of individual components, the complexity of the thromb...

INTRODUCTION Thrombotic disorders are among the major fatal conditions affecting the society. Treatment modalities used for such disorders are either surgical interventions or use of drugs such as urokinase, streptokinase (SK), or tissue plasminogen activators to dissolve the blood clots. These modalities have their own limitations and side effects apart from being expensive. There is a need fo...

TAFI (thrombin activatable fibrinolysis inhibitor) down regulates fibrinolysis after activation by relatively high concentrations of thrombin generated during coagulation via thrombin mediated factor XI activation and subsequent activation of the intrinsic pathway. It is this secondary burst of thrombin that is severely diminished in haemophilia A, a deficiency of coagulation factor VIII. We th...

OBJECTIVE The present study is aimed to investigate in vitro thrombolytic activity of three Bangladeshi medicinal plants Averrhoa bilimbi (Oxalidiaceae), Clerodendrum viscosum (Verbanaceae) and Drynaria quercifolia (Polypodiaceae). MATERIALS AND METHODS Each the plant was extracted with methanol at room temperature and the concentrated methanolic extracts (MEF) were fractionated by the modifi...

Introduction Coagulation alterations after a subarachnoid hemorrhage (aSAH) secondary to aneurysm rupture are frequent and clinically relevant. They may impact negatively in the outcome. The diagnosis of coagulopathy with the standard tests is limited as only the initial part of coagulation process is being assessed. In contrast, thromboelastography provides the whole blood clot information, al...

The recombinant chimeric plasminogen activator, rt-PA-delta FE/scu-PA-e, consisting of amino acids 1 to 3 and 87 to 274 of tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator (scu-PA), has a markedly increased thrombolytic potency following its continuous intravenous infusion in animal models of venous thrombosis (Collen et al...

BACKGROUND Thrombolysis is a dynamic and time-dependent process influenced by the haemodynamic conditions. Currently there is no model that allows for time-continuous, non-contact measurements under physiological flow conditions. The aim of this work was to introduce such a model. METHODS The model is based on a computer-controlled pump providing variable constant or pulsatile flows in a tube...

OBJECTIVE The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) remains to be elucidated. Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis. It remains to be elucidated whether TAFI is directly involved in the pathogenesis of CTEPH. We examined potential involvement of TAFI in the pathogenesis of CTEPH in humans. APPROACH AND RESULTS We enrolled 68 c...

Fibrin fibers form the structural backbone of blood clots; fibrinolysis is the process in which plasmin digests fibrin fibers, effectively regulating the size and duration of a clot. To understand blood clot dissolution, the influence of clot structure and fiber properties must be separated from the effects of enzyme kinetics and perfusion rates into clots. Using an inverted optical microscope ...

A mutant of recombinant tissue-type plasminogen activator (rt-PA), obtained by deletion of residues Lys296 to Gly302 [rt-PA del(K296-G302)], was previously shown to be resistant to inhibition by plasminogen activator inhibitor-1 (PAI-1) (Madison et al, Nature 339:721, 1989). This mutant was obtained by expression of its cDNA in Chinese hamster ovary cells and purification to homogeneity from co...